Crispr Therapeutics (CRSP) Downgraded by Zacks Investment Research
Zacks Investment Research lowered shares of Crispr Therapeutics (NASDAQ:CRSP) from a hold rating to a sell rating in a report released on Thursday.
According to Zacks, “CRISPR Therapeutics AG is a gene-editing company. It focused on the development of transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 gene-editing platform. CRISPR Therapeutics AG is headquartered in Basel, Switzerland. “
CRSP has been the subject of several other reports. Oppenheimer assumed coverage on shares of Crispr Therapeutics in a report on Thursday, December 7th. They set a hold rating for the company. SunTrust Banks raised shares of Crispr Therapeutics from a hold rating to a buy rating in a report on Tuesday, January 23rd. BidaskClub raised shares of Crispr Therapeutics from a hold rating to a buy rating in a report on Thursday, January 4th. Piper Jaffray Companies assumed coverage on shares of Crispr Therapeutics in a report on Friday, December 22nd. They set an overweight rating for the company. Finally, Cann reissued a hold rating on shares of Crispr Therapeutics in a report on Thursday, November 9th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating, four have issued a buy rating and one has assigned a strong buy rating to the stock. The company has a consensus rating of Buy and an average price target of $22.81.
Crispr Therapeutics (NASDAQ:CRSP) last announced its quarterly earnings data on Wednesday, November 8th. The company reported ($0.62) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.60) by ($0.02). The company had revenue of $2.39 million for the quarter, compared to analyst estimates of $3.61 million. Crispr Therapeutics had a negative return on equity of 38.42% and a negative net margin of 466.58%. Crispr Therapeutics’s revenue was up 54.2% on a year-over-year basis. During the same period in the prior year, the business earned ($2.77) earnings per share. equities research analysts anticipate that Crispr Therapeutics will post -2.42 earnings per share for the current year.
In other news, Director Thomas Woiwode sold 1,700 shares of Crispr Therapeutics stock in a transaction dated Friday, November 24th. The shares were sold at an average price of $20.21, for a total value of $34,357.00. Following the completion of the transaction, the director now directly owns 8,218 shares of the company’s stock, valued at approximately $166,085.78. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, insider Tyler Dylan-Hyde sold 66,000 shares of Crispr Therapeutics stock in a transaction dated Tuesday, January 16th. The shares were sold at an average price of $28.03, for a total transaction of $1,849,980.00. Following the completion of the transaction, the insider now directly owns 25,204 shares of the company’s stock, valued at $706,468.12. The disclosure for this sale can be found here. Insiders sold a total of 2,234,504 shares of company stock valued at $44,388,553 over the last ninety days. Company insiders own 39.98% of the company’s stock.
Hedge funds and other institutional investors have recently bought and sold shares of the company. JPMorgan Chase & Co. acquired a new position in shares of Crispr Therapeutics in the 3rd quarter valued at about $536,000. Hershey Trust Co. acquired a new position in shares of Crispr Therapeutics in the 3rd quarter valued at about $768,000. Tiff Advisory Services Inc. acquired a new position in shares of Crispr Therapeutics in the 3rd quarter valued at about $505,000. Allianz Asset Management GmbH acquired a new position in shares of Crispr Therapeutics in the 3rd quarter valued at about $2,384,000. Finally, Granahan Investment Management Inc. MA boosted its holdings in shares of Crispr Therapeutics by 51.7% in the 3rd quarter. Granahan Investment Management Inc. MA now owns 263,746 shares of the company’s stock valued at $4,713,000 after buying an additional 89,839 shares during the period. 21.89% of the stock is owned by institutional investors and hedge funds.
TRADEMARK VIOLATION NOTICE: This report was originally reported by TheOlympiaReport and is owned by of TheOlympiaReport. If you are accessing this report on another site, it was stolen and republished in violation of U.S. and international copyright and trademark legislation. The original version of this report can be accessed at https://theolympiareport.com/2018/01/29/crispr-therapeutics-crsp-downgraded-by-zacks-investment-research.html.
Crispr Therapeutics Company Profile
Crispr Therapeutics AG is a Switzerland-based gene-editing company. The Company focuses on the development of transformative gene-based medicines for serious diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/Cas9 gene-editing platform. CRISPR/Cas9 can be programmed to cut, edit and correct disease-associated deoxyribonucleic acid (DNA) in a patient’s cell.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Crispr Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Crispr Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.